<DOC>
	<DOC>NCT02982200</DOC>
	<brief_summary>A global prospective, multi-center, single-arm, post-market clinical follow-up (PMCF) study conducted to assess the performance of the Medina Embolization Device when used in unruptured and ruptured intracranial aneurysms.</brief_summary>
	<brief_title>Medina Embolization Device In Neurovascular Aneurysm Study</brief_title>
	<detailed_description />
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Intracranial Aneurysm</mesh_term>
	<criteria>Subject has provided written informed consent using the Ethics Committeeapproved consent form and agrees to comply with protocol requirements Subject is 18 85 years old Subject has a ruptured or unruptured saccular intracranial aneurysm amenable to be treated with the Medina Embolization Device Aneurysm is partially thrombosed Aneurysm has been previously treated with surgery or endovascular therapy Subject has had major brain surgery including endovascular procedures within the past 30 days Vessel characteristics (tortuosity, stenosis, morphology) preclude safe endovascular access to the aneurysm Subject is pregnant or breastfeeding or wishes to become pregnant during the length of the study participation The Investigator determines that the validity of the study outcomes may be compromised by the subject's enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Embolization Device</keyword>
	<keyword>Medina</keyword>
	<keyword>Rupture Intracranial Aneurysm</keyword>
	<keyword>Unrupture Intracranial Aneurysm</keyword>
</DOC>